{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-014951","form_type":"8-K","ticker":"BPTH","cik":"0001133818","company_name":"BIO-PATH HOLDINGS, INC.","filed_at":"2023-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.214765+00:00","generated_at":"2026-06-11T09:12:46.662488+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Bio-Path Q2 net loss $4.2M ($0.53/sh); positive AML Phase 2 data for prexigebersen","bullets":["Net loss $4.2M ($0.53/sh) vs $3.0M ($0.42/sh) a year ago; R&D spend up to $3.1M from $1.9M.","Cash $3.4M at June 30, down from $10.4M at Dec 31, 2022; operating cash burn $6.9M for H1 2023.","Positive interim Phase 2 data for prexigebersen in AML: well-tolerated, compelling efficacy in newly diagnosed and relapsed/refractory patients.","Company plans to file for regulatory designations to accelerate pathway for prexigebersen in AML."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-014951","json":"https://secwatch.observer/filing/0001558370-23-014951.json","markdown":"https://secwatch.observer/filing/0001558370-23-014951.md","text":"https://secwatch.observer/filing/0001558370-23-014951.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133818/000155837023014951/0001558370-23-014951-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133818/000155837023014951/bpth-20230815x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T09:12:46.662488+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8a097d1edc2523840618c09d85463e145513c337","claim":"BIO-PATH HOLDINGS, INC. reported the second quarter ended June 30, 2023 results: net income $4.2 million, or $0.53 per share.","evidence_excerpt":"The Company reported a net loss of $4.2 million, or $0.53 per share, for the three months ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133818/000155837023014951/0001558370-23-014951-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"$4.2 million, or $0.53 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}